SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor (ACSPIRE)

This study is actively recruiting.

Principal Investigator: Sina Jasim, MD, MPH

Study Contact
Cameron Smith

Study Website

ClinicalTrials.gov Identifier

The purpose of this study is to learn more about an investigational drug for people with hypercortisolism (higher than normal levels of the adrenal “stress” hormone known as cortisol) related to a benign adrenal tumor, also known as autonomous cortisol secretion (ACS) or adrenal Cushing’s syndrome (aCs). The investigational drug being tested in this study is called SPI-62. It reduces the conversion of cortisone, the inactive precursor, into the active hormone cortisol in the body’s tissues.  Participation lasts 4-5 months and requires at least 5 visits to the research site and 2 scheduled phone calls.